MX2007004769A - Derivado de pirimidina condensado con un anillo no aromatico. - Google Patents

Derivado de pirimidina condensado con un anillo no aromatico.

Info

Publication number
MX2007004769A
MX2007004769A MX2007004769A MX2007004769A MX2007004769A MX 2007004769 A MX2007004769 A MX 2007004769A MX 2007004769 A MX2007004769 A MX 2007004769A MX 2007004769 A MX2007004769 A MX 2007004769A MX 2007004769 A MX2007004769 A MX 2007004769A
Authority
MX
Mexico
Prior art keywords
insulin
pyrimidine derivative
action
nonaromatic ring
diabetes
Prior art date
Application number
MX2007004769A
Other languages
English (en)
Inventor
Yasuhiro Yonetoku
Kenji Negoro
Kenichi Onda
Masahiko Hayakawa
Daisuke Sasuga
Takahiro Nigawara
Kazuhiko Iikubo
Hiroyuki Moritomo
Shigeru Yoshida
Takahide Ohishi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2007004769A publication Critical patent/MX2007004769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan nuevos derivados de pirimidina condensados con un anillo no aromatico seleccionado de dihidrotiofeno, dihidrofuran, porcion de cicloalcano, y lo similar o sales farmaceuticamente aceptables de los mismos; y una composicion farmaceutica comprendiendo dicho compuesto como un ingrediente activo. Estos compuestos muestran excelente actividad de promocion en secrecion de insulina y actividad contra hiperglicemia. Por lo tanto, las composiciones farmaceuticas comprendiendo tales compuestos como ingredientes activos, en base a estas acciones, son utiles para tratar y/o prevenir diabetes dependiente de insulina (diabetes tipo 1), diabetes no dependiente de insulina (diabetes tipo 2), enfermedades resistentes a insulina, obesidad y lo similar.
MX2007004769A 2004-10-20 2005-10-17 Derivado de pirimidina condensado con un anillo no aromatico. MX2007004769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004305374 2004-10-20
PCT/JP2005/019000 WO2006043490A1 (ja) 2004-10-20 2005-10-17 非芳香環縮合ピリミジン誘導体

Publications (1)

Publication Number Publication Date
MX2007004769A true MX2007004769A (es) 2007-06-25

Family

ID=36202906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004769A MX2007004769A (es) 2004-10-20 2005-10-17 Derivado de pirimidina condensado con un anillo no aromatico.

Country Status (15)

Country Link
US (1) US7947690B2 (es)
EP (1) EP1803710A4 (es)
JP (1) JP4775767B2 (es)
KR (1) KR20070084035A (es)
CN (1) CN101044123B (es)
AU (1) AU2005297743A1 (es)
BR (1) BRPI0516237A (es)
CA (1) CA2584666C (es)
IL (1) IL182641A0 (es)
MX (1) MX2007004769A (es)
NO (1) NO20072542L (es)
RU (1) RU2007118653A (es)
TW (1) TW200621257A (es)
WO (1) WO2006043490A1 (es)
ZA (1) ZA200703947B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953417B (zh) * 1996-09-04 2010-12-29 英特托拉斯技术公司 一种从用户站点向外部站点发布使用数据的方法
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
TW200804358A (en) 2006-03-31 2008-01-16 Res Found Itsuu Lab Novel compound having heterocycle
KR101281962B1 (ko) 2006-04-11 2013-07-08 아레나 파마슈티칼스, 인크. 특정 개체에게서 골 질량을 증가시키는 데에 유용한 화합물을 확인하기 위해 ｇｐｒ119 수용체를 사용하는 방법
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8329701B2 (en) * 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
WO2008006032A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2009000087A1 (en) * 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
RU2486181C2 (ru) * 2007-07-05 2013-06-27 Эррэй Биофарма Инк. Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2422733T3 (es) 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
RU2473549C2 (ru) * 2008-07-31 2013-01-27 Дженентек, Инк. Пиримидиновые соединения, композиции и способы применения
CN102480961A (zh) * 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
US20110021515A1 (en) * 2009-07-24 2011-01-27 Takeda Pharmaceutical Company Limited Dihyrofuropyrmindine compounds
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
KR101469334B1 (ko) * 2009-11-12 2014-12-04 에프. 호프만-라 로슈 아게 Ｎ-9-치환된 퓨린 화합물, 조성물 및 사용 방법
BR112012011147A2 (pt) * 2009-11-12 2021-09-08 F.Hoffmann-La Roche Ag Composto, composição farmacêutica e uso de um composto.
EP2610252A4 (en) 2010-08-26 2013-09-04 Kowa Co NOVEL PROCESS FOR THE PRODUCTION OF ISOQUINOLINE DERIVATIVES AND THEIR SALTS
CN103539791B (zh) 2010-09-22 2017-01-11 艾尼纳制药公司 Gpr119 受体调节剂和对与其相关的障碍的治疗
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
CN103857395A (zh) 2011-04-01 2014-06-11 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
CN102875567B (zh) * 2011-07-15 2015-03-11 天津药物研究院 一类含哌嗪化合物、制备及用途
WO2014124860A1 (en) * 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
TW201512189A (zh) 2013-04-16 2015-04-01 Gruenenthal Chemie 新型被取代之嘧啶縮合化合物
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3060525A1 (en) 2017-05-22 2018-11-29 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
DE3888215T2 (de) 1987-01-21 1994-09-08 Merck & Co Inc Piperazinylpyrimidine als beta-adrenergische Rezeptoren blockierende Mittel.
US4871739A (en) * 1987-01-21 1989-10-03 Merck & Co., Inc. Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
US4889856A (en) * 1987-08-31 1989-12-26 Merck & Co., Inc. 7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
JPH04224580A (ja) 1990-12-25 1992-08-13 Nippon Soda Co Ltd ピリミジン誘導体、その製造方法及び農園芸用殺菌剤
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19904710A1 (de) 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE60120193T2 (de) 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
KR20030034232A (ko) * 2000-09-29 2003-05-01 닛뽕소다 가부시키가이샤 티에노피리미딘 화합물 및 그 염 및 제조방법
EP1474147B1 (en) * 2001-12-07 2010-05-05 Vertex Pharmaceuticals Incorporated Pyrimidine-based compounds useful as gsk-3 inhibitors
US7423044B2 (en) * 2002-09-05 2008-09-09 Wyeth Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP4224580B2 (ja) 2003-02-28 2009-02-18 独立行政法人産業技術総合研究所 層状オルガノシリカナノ複合体およびその製造方法
US7223766B2 (en) 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
AU2004263515A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
BRPI0516751A (pt) * 2004-09-30 2008-09-16 Tibotec Pharm Ltd pirimidinas bicìclicas que inibem hcv

Also Published As

Publication number Publication date
US7947690B2 (en) 2011-05-24
US20080070896A1 (en) 2008-03-20
JP4775767B2 (ja) 2011-09-21
CN101044123A (zh) 2007-09-26
CA2584666A1 (en) 2006-04-27
KR20070084035A (ko) 2007-08-24
WO2006043490A1 (ja) 2006-04-27
EP1803710A4 (en) 2009-08-26
JPWO2006043490A1 (ja) 2008-05-22
EP1803710A1 (en) 2007-07-04
NO20072542L (no) 2007-07-18
AU2005297743A1 (en) 2006-04-27
CN101044123B (zh) 2010-09-08
IL182641A0 (en) 2007-07-24
RU2007118653A (ru) 2008-11-27
TW200621257A (en) 2006-07-01
BRPI0516237A (pt) 2008-08-26
ZA200703947B (en) 2008-08-27
CA2584666C (en) 2011-12-06

Similar Documents

Publication Publication Date Title
TW200621257A (en) Pyrimidine derivative fused with nonaromatic ring
EP1806347A4 (en) PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
TW200617001A (en) Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same
WO2005082414A3 (en) Concomitant drugs of a sulfonamide and another therapeutic agent
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
NO20065904L (no) Terapeutiske forbindelser
EP1609798A4 (en) CONDENSED HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, AND MEDICAL USE THEREOF
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
IL139227A0 (en) N-substituted aminotetralins as ligands for the neuropeptide yy5 receptor useful in the treatment of obesity and other disorders
TW200606129A (en) Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
IN2015DN01132A (es)
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
JP2007529532A5 (es)
WO2008050101A3 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
EP2422798A3 (en) Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
MY146279A (en) Compounds affecting glucokinase
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
WO2005105110A3 (en) Doxepin analogs and methods of use thereof
WO2005117895A8 (en) Compositions comprising meloxicam
JO2937B1 (en) Tight muscles of the peptide vascular tensioner receptor
TW200634001A (en) Novel compounds
WO2006036981A3 (en) Small molecule modulators of cytokine activity
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal